The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2016 | Virus-specific T cells – effectiveness, safety profile and use
Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the safety and effectivness of virus-specific T cells and their use in transplant patients. According to Dr Leen, there is a lot of research focusing around the use of algorithms to help phyisicans choose the right product for their patients and the next step would be a registration trial. She further describes how referrals usually come from transplant physicians. In order to provide the virus-specific T cells to the patients, they require the HLA characteristics of the patient and the details of their infection.
Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
